Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onglyza

FDA sets new date for Eliquis review in atrial fibrillation

US regulator had asked for more data from Pfizer and BMS

Novo Nordisk invests $100m in research in China

Expands existing site in Beijing

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

FDA launches safety probe into Boehringer’s Mirapex

Regulator concerned about potential heart risk link to Parkinson's disease drug

- PMLiVE

Boehringer cancer R&D programme bears first fruit

Submits afatinib in Europe to treat lung cancer

J&J files intravenous Simponi formulation in US

FDA approval would complement J&J’s current subcutaneously-administered product

Diabetes apps present usability problems for older adults

Researchers find a range of potential design problems with smartphone apps

Cornerstone slumps as FDA panel votes down lead pipeline drug

US pharma company asked to conduct new trials for its hyponatremia treatment

- PMLiVE

Boehringer-Lilly tap into behavioural change for online diabetes programme

Part of the partners' Tradjenta marketing, My Well Planner offers personalised educational resources

- PMLiVE

FDA urged to give biosimilar medicines distinct scientific names

Alliance for Safe Biologic Medicines highlights safety concerns if different products have same name

- PMLiVE

FDA clears Sanofi’s oral MS drug Aubagio

Will compete with Novartis’ Gilenya

- PMLiVE

J&J responds to FDA concerns over Xarelto in ACS

Responds to regulator about missing clinical trial data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links